Characterization of a Novel Small Molecule Subtype Specific Estrogen-Related Receptor α Antagonist in MCF-7 Breast Cancer Cells

por Chisamore, Michael J., Cunningham, Michael E., Flores, Osvaldo, Wilkinson, Hilary A., Chen, J. Don
Publicado 2009

Identification and characterization of lipopolysaccharide binding protein (LBP) as an estrogen receptor α specific serum biomarker

por Chisamore, Michael J, Hong, Kwok-lam Karen, Cheng, Chun, Alves, Stephen E, Rohrer, Susan P, Wilkinson, Hilary A
Publicado 2012

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

por Schöffski, Patrick, Bahleda, Rastislav, Wagner, Andrew J., Burgess, Melissa A., Junker, Niels, Chisamore, Michael, Peterson, Patrick, Szpurka, Anna M., Ceccarelli, Matteo, Tap, William D.
Publicado 2023

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma

por Nishihori, Taiga, Hoffman, James E., Huff, Anne, Kapoor, Gurpreet S., Eleftheriadou, Ioanna, Zajic, Stefan, Urbano, Alisa, Suchindran, Sunil, Chisamore, Michael, D’Souza, Jimson W., Faitg, Thomas, Rapoport, Aaron P.
Publicado 2022

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

por Pujol, Jean-Louis, Vansteenkiste, Johan, Paz-Ares Rodríguez, Luis, Gregorc, Vanesa, Mazieres, Julien, Awad, Mark, Jänne, Pasi A., Chisamore, Michael, Hossain, Anwar M., Chen, Yanyun, Beck, J. Thaddeus
Publicado 2021

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

por Rugo, Hope S., Kabos, Peter, Beck, J. Thad, Jerusalem, Guy, Wildiers, Hans, Sevillano, Elena, Paz-Ares, Luis, Chisamore, Michael J., Chapman, Sonya C., Hossain, Anwar M., Chen, Yanyun, Tolaney, Sara M.
Publicado 2022

Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice

por Thomas, Stacy K., Wattenberg, Max M., Choi-Bose, Shaanti, Uhlik, Mark, Harrison, Ben, Coho, Heather, Cassella, Christopher R., Stone, Meredith L., Patel, Dhruv, Markowitz, Kelly, Delman, Devora, Chisamore, Michael, Drees, Jeremy, Bose, Nandita, Beatty, Gregory L.
Publicado 2023

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

por Cohen, Ezra E.W., Nabell, Lisle, Wong, Deborah J., Day, Terry, Daniels, Gregory A., Milhem, Mohammed, Deva, Sanjeev, Jameson, Michael, Guntinas-Lichius, Orlando, Almubarak, Mohammed, Strother, Matthew, Whitman, Eric, Chisamore, Michael, Obiozor, Cynthia, Bagulho, Teresa, Gomez-Romo, Jose, Guiducci, Cristiana, Janssen, Robert, Gamelin, Erick, Algazi, Alain P.
Publicado 2022

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

por Verset, Gontran, Borbath, Ivan, Karwal, Mark, Verslype, Chris, Van Vlierberghe, Hans, Kardosh, Adel, Zagonel, Vittorina, Stal, Per, Sarker, Debashis, Palmer, Daniel H., Vogel, Arndt, Edeline, Julien, Cattan, Stephane, Kudo, Masatoshi, Cheng, Ann-Lii, Ogasawara, Sadahisa, Daniele, Bruno, Chan, Stephen L., Knox, Jennifer J., Qin, Shukui, Siegel, Abby B., Chisamore, Michael, Hatogai, Ken, Wang, Anran, Finn, Richard S., Zhu, Andrew X.
Publicado 2022

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells

por Li, Huiyu, Liu, Zhida, Liu, Longchao, Zhang, Hongyi, Han, Chuanhui, Girard, Luc, Park, Hyunsil, Zhang, Anli, Dong, Chunbo, Ye, Jianfeng, Rayford, Austin, Peyton, Michael, Li, Xiaoguang, Avila, Kimberley, Cao, Xuezhi, Hu, Shuiqing, Alam, Md Maksudul, Akbay, Esra A., Solis, Luisa M., Behrens, Carmen, Hernandez-Ruiz, Sharia, Lu, Wei, Wistuba, Ignacio, Heymach, John V., Chisamore, Michael, Micklem, David, Gabra, Hani, Gausdal, Gro, Lorens, James B., Li, Bo, Fu, Yang-Xin, Minna, John D., Brekken, Rolf A.
Publicado 2022

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

por Postel-Vinay, Sophie, Lam, Vincent K, Ros, Willeke, Bauer, Todd M, Hansen, Aaron R, Cho, Daniel C, Stephen Hodi, F, Schellens, Jan H M, Litton, Jennifer K, Aspeslagh, Sandrine, Autio, Karen A, Opdam, Frans L, McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M, Ahlers, Christoph M, Zhou, Helen, Struemper, Herbert, Gorman, Shelby A, Watmuff, Maura, Yablonski, Kaitlin M, Yanamandra, Niranjan, Chisamore, Michael J, Schmidt, Emmett V, Hoos, Axel, Marabelle, Aurelien, Weber, Jeffrey S, Heymach, John V
Publicado 2023

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

por Yadavilli, Sapna, Waight, Jeremy D., Brett, Sara, Bi, Meixia, Zhang, Tianqian, Liu, Yao-Bin, Ellis, Catherine, Turner, David C., Hahn, Ashleigh, Shi, Hong, Seestaller-Wehr, Laura, Jing, Junping, Xie, Qing, Shaik, Jafar Sadik, Ji, Xiao, Gagnon, Robert, Fieles, William, Hook, Laura, Grant, Steven, Hopley, Stephanie, DeYoung, M. Phillip, Blackwell, Christina, Chisamore, Michael, Biddlecombe, Robert, Figueroa, David J., Hopson, Christopher B., Srinivasan, Roopa, Smothers, James, Maio, Michele, Rischin, Danny, Olive, Daniel, Paul, Elaine, Mayes, Patrick A., Hoos, Axel, Ballas, Marc
Publicado 2023